Hormonal interactions in ovarian cancer

Hematology/Oncology Clinics of North America

Volumn 13, Issue 1, 1999, Pages 145-161

  Emons, G ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; CLOMIFENE; CONTRACEPTIVE AGENT; ESTROGEN; FOLLITROPIN; GESTAGEN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; LUTEINIZING HORMONE; SEX HORMONE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 0032965873     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70158-1     Document Type: Article

References (103)

1. G.M. Abu-Jawdeh T.W. Jacobs J. Niloff Estrogen receptor expression is a common feature of ovarian borderline tumors Gynecol Oncol 60 1996 301
2. J.D. Ahlgren N.M. Ellison Gottlieb R.J. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program J Clin Oncol 11 1993 1957
3. E. Banks Beral V, Reeves G: The epidemiology of epithelial ovarian cancer: A review International Journal of Gynecologic Cancer 7 1997 425
4. S. Batra C.S. Iosif Elevated concentrations of antiestrogen binding sites in membrane fractions of human ovarian tumors Gynecol Oncol 60 1996 228
5. A.L. Borresen Oncogenesis in ovarian cancer Acta Obstet Gynecol Scand 71 suppl 155 1992 25
6. A.W. Brandenberger M.K. Tee R.B. Jaffe Estrogen receptor alpha (ER-α) and beta (ER-β) mRNAs in normal ovary, ovarian cystadenocarcinoma and ovarian cancer cell lines: Down-regulation of ER-β in neoplastic tissues J Clin Endocrinol Metab 83 1998 1025
7. R.E. Bristow B.Y. Karlan Ovulation induction, infertility, and ovarian cancer risk Fertil Steril 66 1996 499
8. R.E. Bristow B.Y. Karlan The risk of ovarian cancer after treatment for infertility Curr Opin Obstet Gynecol 8 1996 32
9. S.Z. Bu D.L. Yin X.H. Ren Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian cancer cell lines Cancer 79 1997 1944
10. J.T. Casagrande E.W. Louie M.C. Pike Incessant ovulation and ovarian cancer Lancet 2 1979 170
11. S. Chadha B.R. Rao B.J. Slotman An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors Hum Pathol 24 1993 90
12. G.M. Clinton W. Hua Estrogen action in human ovarian cancer Crit Rev Oncol Hematol 25 1997 1
13. J.P. Connor R.E. Buller P.M. Conn Effects of GnRH analogs on six ovarian cancer cell lines in culture Gynecol Oncol 54 1994 80
14. D.W. Cramer W.R. Welch Determinants of ovarian cancer risk. II Inferences regarding pathogenesis J Natl Cancer Inst 71 1993 717
15. R.A. Eeles S. Tan I. Wiltshaw Hormone replacement therapy and survival after surgery for ovarian cancer BMJ 302 1991 259
16. T. Ehlen L. Dubeau Loss of heterozygosity on chromosomal segments 6p, 6q and 11p in human ovarian carcinomas Oncogene 5 1990 219
17. G. Emons V. Müller O. Ortmann Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines International Journal of Oncology 9 1996 1129
18. G. Emons O. Ortmann M. Becker High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines Cancer Res 54 1993 5439
19. G. Emons O. Ortmann Schulz K.-D. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells Trends in Endocrinology and Metabolism 8 1997 355
20. G. Emons O. Ortmann Schulz K.-D. GnRH analogues in ovarian, breast and endometrial cancers Lunenfeld B. Insler V. GnRH Analoges. The State of the Art 1996 1996 Parthenon Carnforth 95
21. G. Emons O. Ortmann Teichert H.-M. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma Cancer 78 1996 1452
22. G. Emons A.V. Schally The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers Hum Reprod 9 1994 1364
23. G. Emons K.D. Schulz Growth regulation of epithelial ovarian cancer by hormones, peptide growth factors, and cytokines J.R. Pasqualini B.S. Katzenellenbogen Hormone-Dependent Cancer 1996 Marcel Dekker New York 509
24. A. Ercoli G. Scambia R. De Vincenzo Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: Enhancement of DNA platination as a possible mechanism Cancer Lett 108 1996 7
25. M.F. Fathalla Incessant ovulation—A factor in ovarian neoplasia? Lancet 2 1971 163
26. R.S. Freedman P.B. Saul C.L. Edwards Ethinyl estradiol and medroxy-progesterone acetate in patients with epithelial ovarian carcinoma: A phase II study Cancer Treatment Reports 70 1986 369
27. J. Fujimoto S. Ichigo R. Hirose Expression of estrogen receptor exon 5 splicing variant (ER 5 SV) mRNA in gynaecological cancers J Steroid Biochem Mol Biol 60 1997 25
28. K.R. Geisinger M.E. Berens Y. Duckett The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro Cancer 65 1990 1055
29. J.P. Geisler M.C. Wiemann G.A. Miller Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary Gynecol Oncol 60 1996 424
30. A.K. Godwin R.P. Perez S.W. Johnson Growth regulation of ovarian cancer Hematol Oncol Clin North Am 6 1992 829
31. A.K. Godwin J.R. Testa T.C. Hamilton The biology of ovarian cancer development Cancer 71 1993 530
32. S.E. Hankinson G.A. Colditz D.J. Hunter A prospective study of reproductive factors and risk of epithelial ovarian cancer Cancer 76 1995 284
33. K.J. Helzlsouer A.J. Albery G.B. Gordon Serum gonadotropins and steroid hormones and the development of ovarian cancer JAMA 274 1995 1926
34. R.E. Hempling C. Wong M.S. Piver Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case control study Obstet Gynecol 89 1997 1012
35. J. Hofmann F. Hölzel R. Hackenberg Characterization of epidermal growth factor related proteins from human urinary chorionic gonadotropin J Endocrinol 123 1989 333
36. A. Imai T. Ohno K. Iida Gonadotropin-releasing hormone receptors in gynecological tumors Cancer 74 1994 2555
37. A. Imai T. Ohno K. Takahashi Lack of evidence for aromatase expression in human ovarian epithelial carcinoma Ann Clin Biochem 31 1994 65
38. A. Imai H. Takagi T. Furui Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane Cancer 77 1996 132
39. A. Imai H. Takagi S. Horibe Coupling of gonadotropin releasing hormone receptor to Gi protein in human reproductive tract tumors J Clin Endocrinol Metab 81 1996 3249
40. G. Irmer C. Bürger R. Müller Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma Cancer Res 55 1995 817
41. S.S. Kakar W.E. Grizzle J.D. Neill The nucleotide sequences human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary Mol Cell Endocrinol 106 1994 145
42. S. Kammerman R.J. Demopoulos C. Raphael Gonadotropic hormone binding to human ovarian tumors Hum Pathol 12 1981 886
43. R.J. Kaufman Management of advanced ovarian carcinoma Med Clin North Am 50 1996 845
44. J.J. Kavanagh J.T. Wharton W.S. Roberts Androgen therapy in the treatment of refractory epithelial ovarian cancer Cancer Treatment Reports 71 1987 537
45. D.G. Kieback S.K. McCammant M.F. Press Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor Cancer Res 53 1993 5188
46. Y. Kikuchi J. Hirata T. Kita Enhancement of antiproliferative effects of cis-diamminedichloroplatinum (II) by clomiphene and tamoxifen in human ovarian cancer cells Gynecol Oncol 49 1993 365
47. F. Kommoss Common epithelial ovarian cancer: Endocrine factors, hormonal therapy, and new aspects concerning the expression of sex steroid receptors J.R. Pasqualini B.S. Katzenellenbogen Hormone-Dependent Cancer 1996 Marcel Dekker New York 541
48. S. Kullander A. Rausing A.V. Schally LH-RH agonist treatment in ovarian cancer Klijn J.G.M. Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents 1987 Raven Press New York 353
49. H. Kuroda J. Konishi M. Mandai Ovarian cancer in infertile women during or after ovulation-induction therapy: Expression of LH/hCG receptors and sex steroid receptors International Journal of Gynecologic Cancer 7 1997 451
50. H. Kuroda M. Mandai J. Konishi Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: Possible role of up-regulation of insulin-like growth factor-1 by HCG Int J Cancer 76 1998 571
51. G. Kvale J. Heuch S. Nillsen Reproductive factors and risk of ovarian cancer: A prospective study Int J Cancer 42 1989 246
52. J.H. Lee J.J. Kavanagh D.M. Wildrich Frequent loss of heterozygosity on chromosomes 6q, 11 and 17 in human ovarian carcinomas Cancer Res 50 1990 2724
53. D.J. Lindner E.C. Borden Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis Int J Cancer 71 1997 456
54. A. Lopez A. Tessadrelli A.P. Kudelka Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer Int J Gynecol Cancer 6 1996 15
55. M. Mandai J. Konishi H. Kuroda Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas Eur J Cancer 33 1997 1501
56. A. Manetta L. Gamboa-Vujicic P. Parades Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) Fertil Steril 63 1995 282
57. E.F. McClay K.D. Albright J.A. Jones Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines Br J Cancer 70 1994 449
58. L.L. McCluskey L. Dubeau Biology of ovarian cancer Curr Opin Oncol 9 1997 465
59. W.R. Miller S.P. Langdon Steroid hormones and cancer: II Lessons from experimental systems Eur J Surg Oncol 23 1997 72
60. M. Miyazaki A. Nagy A.V. Schally Growth inhibition of human ovarian cancers by cytostatic analogs of luteinizing hormone releasing hormone J Natl Cancer Inst 89 1997 1803
61. B.J. Moosgaard G. Schau O. Lidegaard Infertility, fertility drugs, and invasive ovarian cancer: A case-control study Fertil Steril 67 1997 1005
62. R. Mortel P.G. Satyaswaroop A.V. Schally Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH:OVCAR-3 in the nude mouse Gynecol Oncol 23 1986 254
63. R. Nakano M. Kitayama M. Yamoto Localization of gonadotropin binding sites on human ovarian neoplasms Am J Obstet Gynecol 161 1989 905
64. T. Ohno A. Imai T. Furui Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma Am J Obstet Gynecol 169 1993 605
65. K. Ohtani H. Sakamoto H. Satoh Stimulatory effects of follicle stimulating hormone on the proliferation of ovarian cancer cell line in vitro and in vivo Acta Obstetrica Japananica 44 1992 717
66. K. Ohtani Effects of gonadotropin on the growth of malignant ovarian neoplasms assessed by subrenal capsule assay Nippon Sanka Fujinka Gakki Zasshi 42 1990 579
67. R. Olshausen Die Krankheiten der Ovarien, Ätiologie Billroth T. Handbuch der Frauenkrankheiten vol 6 1877 Enke Stuttgart 74
68. R.F. Ozols Treatment of recurrent ovarian cancer: Increasing options—“Recurrent” results [editorial] J Clin Oncol 15 1997 2177
69. I. Pályi B. Vincze A. Kálnay Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines Cancer Detect Prev 20 1996 146
70. F. Parrazzini S. Franceschi La Vecchia The epidemiology of ovarian cancer Gynecol Oncol 43 1991 9
71. C.M. Peterson C.J. Jolles D.T. Carell GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience Gynecol Oncol 52 1994 26
72. C.M. Peterson S.J. Zimniski A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse Obstet Gynecol 76 1990 264
73. 6-LHRH: A preliminary report Cancer Lett 41 1988 105
74. M.A. Quinn H.W.G. Baker R. Rome Response of a mucinous ovarian tumor of borderline malignancy to human chorionic gonadotropin Obstet Gynecol 61 1983 121
75. M.A. Quinn R.M. Rome M. Cauchi Steroid receptors and ovarian tumours: Variation within primary tumors and between primary tumors and metastases Gynecol Oncol 31 1988 424
76. H. Rajaniemi A. Kauppila L. Rönnberg LH (hCG) receptor in benign and malignant tumors of human ovary Acta Obstet Gynecol Scand suppl 101 1998 83
77. R.B. Rao B.J. Slotman Endocrine factors in common epithelial ovarian cancer Endocr Rev 12 1991 12
78. H.A. Risch Estrogen replacement therapy and risk of epithelial ovarian cancer Gynecol Oncol 63 1996 254
79. C. Rodriguez E.E. Calle R.J. Coates Estrogen replacement therapy and fatal ovarian cancer Am J Epidemiol 141 1995 28
80. F.V. Rose E.R. Barnea Response of human ovarian carcinoma cell lines to antiprogestin mifepristone Oncogene 12 1996 999
81. M.A. Rossing J.R. Daling N.S. Weiss Ovarian tumors in a cohort of infertile women N Engl J Med 331 1994 771
82. M. Sawada N. Terada A. Wada Estrogen and androgen-responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice Int J Cancer 45 1990 359
83. G. Scambia B. Panici G. Ferrandina Prognostic significance of receptors for epidermal growth factor, estrogen, and progesterone in ovarian cancer Ann N Y Acad Sci 784 1996 202
84. G. Scambia F.O. Ranelletti P.B. Panici Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumors Eur J Cancer 28A 1992 1885
85. J.M. Schildkraut E. Bastos A. Berchuk Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer J Natl Cancer Inst 89 1997 932
86. J.J. Schlesselman Cancer of the breast and reproductive tract in relation to use of oral contraceptives Contraception 40 1989 1
87. P. Scirpa D. Mango M. Liberati Response to human chorionic gonadotropin in patients with ovarian tumors Acta Obstet Gynecol Scand 67 1988 589
88. J.S. Scott How to induce ovarian cancer and how not to BMJ 289 1984 781
89. Y. Shirahige C. Cook J. Pinski Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice International Journal of Oncology 5 1994 1031
90. A. Shushan O. Paltiel J. Iscovich Human menopausal gonadotropin and the risk of epithelial ovarian cancer Fertil Steril 65 1996 13
91. W.E. Simon M. Albrecht M. Hänsel Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones J Natl Cancer Inst 70 1983 839
92. V. Siskind A. Green C. Bain Breast feeding, menopause, and epithelial ovarian cancer Epidemiology 8 1997 188
93. B.J. Slotman Rationale for the Use of Endocrine Therapy in Ovarian Cancer 1990 Thesis Publishers Amsterdam
94. B.V. Stadel The etiology and prevention of ovarian cancer Am J Obstet Gynecol 123 1975 772
95. R.L. Stouffer M.S. Grodin J.R. Davis Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers J Clin Endocrinol Metab 59 1984 441
96. M.A. Thompson M.D. Adelson L.M. Kaufman Lupron retards proliferation of ovarian tumor cells cultured in serum free medium J Clin Endocrinol Metab 72 1991 1036
97. M.G. Tibiletti B. Bernasconi D. Furlan Early involvement of 6q in surface epithelial ovarian tumors Cancer Res 56 1996 4493
98. A. Venn L. Watson J. Lumly Breast and ovarian cancer incidence after infertility and in vitro fertilization Lancet 346 1995 995
99. A.S. Whittemore R. Harris J. Itnyre Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II Invasive epithelial ovarian cancers in white women Am J Epidemiol 136 1992 1184
100. A.S. Whittemore A. McGuire Ovulation, p53 mutations, and ovarian cancer—A causal link? [editorial] J Natl Cancer Inst 89 1997 906
101. J. Wimalasena D. Meehan C. Cavallo Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins Gynecol Oncol 41 1991 56
102. T. Yano J. Pinski G. Halmos Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75 Proc Natl Acad Sci USA 91 1994 7090
103. T. Yano Pinski, J, Radulovic S, et al: Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-release hormone Proc Natl Acad Sci USA 91 1994 1701